News

Nerviano 9 May 2023_ Nerviano Medical Sciences Srl (NMS) was delighted to be the title sponsor of  the 1st European Cancer Dependency Map Symposium, together with Astra Zeneca. This is an international event organized by scientists at Human Technopole, EMBL – European Bioinformatics Institute (Cambridge, UK), Wellcome Sanger Institute (Cambridge, UK) and ETH Zurich (Switzerland) taking place at Human Technopole in Milan on May 8-9, 2023.
(Click the title for the complete article)

Nerviano 21 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to be selected as Plenary Session highlights of the AACR (American Association for Cancer Research) Annual Meeting 2023 for the data from the First-In-Human study of NMS-03592088 – a novel, potent inhibitor of FLT3, KIT and CSF1R. The Phase 1 clinical trial data were presented during an oral scientific session on 16 April.
(Click the title for the complete article)

Nerviano 16 April 2023_Nerviano Medical Sciences Srl, a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the First-In-Human study of NMS-03592088, a novel, potent inhibitor of FLT3, KIT and CSF1R were presented during an oral scientific session at the American Association for Cancer Research 2023 Annual Meeting in Orlando, Florida.
(Click the title for the complete article)

Nerviano, 05 April 2023 – Nerviano Medical Sciences Srl,a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that two posters will be presented at the upcoming AACR annual meeting which will be held April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida.
(Click the title for the complete article)

NMS group has joined the WHP program since 2017. The Workplace Health Promotion (WHP) is the combined efforts of employers, employees and society to improve the health and well-being of people at work. The promotion of a comfortable and healthy workplace has been one of the goals of NMS group since 2017.
(Click the title for the complete article)

NERVIANO, 4 April 2023 – Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that data from the  Phase I/II clinical study of NMS-03592088 in Acute Myeloid Leukemia  will be reported in an oral presentation by Dr. Antonio Curti, MD, PhD,  IRCCS Azienda Ospedaliero-Universitaria di Bologna, at the upcoming AACR Annual Meeting which will be held April 14 – 19, Orange County Convention Center, Orlando, Florida.
(Click the title for the complete article)

NERVIANO, IT March 1st 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Anders Elm Pedersen MD, PhD, DMSc., has joined Global Clinical Development as Senior Medical Director to lead the clinical strategy and clinical development plans of the Company’s ever-growing pipeline. Anders brings extensive research, clinical development and medical affairs experience to NMS, and authored more than 80 research publications within preclinical and clinical research .
(Click the title for the complete article)

01 February 2023_Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Gergely Balint, MSc, has joined the Global Asset Leadership Team to lead the development and maximize the value of its MPS1 Inhibitor Asset, NMS-01940153E (NMS-153).
(Click the title for the complete article)

January 12, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline. Terrence West, MBA, joins as New Business, Virtual CEO.
(Click the title for the complete article)

MPS1 Kinase Inhibitor Shows Clinical Activity in Primary Liver Cancer

The targeted drug NMS-01940153E, a monopolar spindle 1 (MPS1) kinase inhibitor, has shown signs of clinical activity in a Phase I study of patients with relapsed or refractory unresectable hepatocellular carcinoma (HCC). The study findings were reported at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
(Click the title for the complete article)